WO2011064758A3 - Fusion proteins of immunoglobulin fc and interferon- alpha - Google Patents
Fusion proteins of immunoglobulin fc and interferon- alpha Download PDFInfo
- Publication number
- WO2011064758A3 WO2011064758A3 PCT/IB2010/055474 IB2010055474W WO2011064758A3 WO 2011064758 A3 WO2011064758 A3 WO 2011064758A3 IB 2010055474 W IB2010055474 W IB 2010055474W WO 2011064758 A3 WO2011064758 A3 WO 2011064758A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferon
- alpha
- immunoglobulin
- fusion proteins
- fusion protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides an interferon-alpha immunoglobulin Fc fusion protein and use of the fusion protein in the treatment of a condition alleviated by the administration of interferon- alpha, such as a liver disorder, for example hepatitis and in particular hepatitis C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26500109P | 2009-11-30 | 2009-11-30 | |
US61/265,001 | 2009-11-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011064758A2 WO2011064758A2 (en) | 2011-06-03 |
WO2011064758A3 true WO2011064758A3 (en) | 2011-08-04 |
Family
ID=43640103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/055474 WO2011064758A2 (en) | 2009-11-30 | 2010-11-29 | Fusion protein |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011064758A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106456809A (en) * | 2013-12-03 | 2017-02-22 | 韦尔特生物分子医药有限责任公司 | Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2832581C (en) | 2011-04-08 | 2022-08-23 | Yumei Xiong | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
KR20130049671A (en) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | Method for preparation of biological active polypeptide conjugate |
EP2807266B1 (en) | 2012-01-26 | 2020-01-15 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
AR090281A1 (en) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX |
WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
BR112015018104A2 (en) | 2013-01-30 | 2017-11-21 | Ngm Biopharmaceuticals Inc | modified gdf15 polypeptides, their use, compositions comprising them and sterile container comprising said compositions |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
BR112016002213A2 (en) | 2013-07-31 | 2017-08-29 | Amgen Inc | CONSTRUCTS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) |
LT6164B (en) * | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Fused proteins of interferon alpha 5 with another cytokine and process for production thereof |
AU2015242657B2 (en) * | 2014-03-31 | 2020-05-21 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage |
EA035581B1 (en) | 2014-07-30 | 2020-07-10 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Compositions and methods of use for treating metabolic disorders |
TN2017000113A1 (en) | 2014-10-31 | 2018-07-04 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
PE20190126A1 (en) | 2016-03-31 | 2019-01-17 | Ngm Biopharmaceuticals Inc | BINDING PROTEINS AND METHODS OF USING THEM |
CN107254482A (en) * | 2017-07-18 | 2017-10-17 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving Recombinant Swine interferon alpha fusion protein antiviral activity |
CN107177613A (en) * | 2017-07-18 | 2017-09-19 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving restructuring Porcine interferon-gamma fusion protein antiviral activity |
CN107129994A (en) * | 2017-07-18 | 2017-09-05 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving canine recombinant interferon beta fusion protein antiviral activity |
CN107326037A (en) * | 2017-07-18 | 2017-11-07 | 哈尔滨紫霞生物科技有限公司 | A kind of method for improving Recombinant Swine interferon beta fusion protein antiviral activity |
MX2020010659A (en) | 2018-04-09 | 2020-10-28 | Amgen Inc | Growth differentiation factor 15 fusion proteins. |
US11136353B2 (en) | 2019-04-15 | 2021-10-05 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof |
US11058725B2 (en) | 2019-09-10 | 2021-07-13 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058572A1 (en) * | 1998-05-08 | 1999-11-18 | Cambridge University Technical Services Limited | Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis |
WO2000069913A1 (en) * | 1999-05-19 | 2000-11-23 | Lexigen Pharmaceuticals Corp. | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
WO2002072605A2 (en) * | 2001-03-07 | 2002-09-19 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2004074486A2 (en) * | 2003-02-18 | 2004-09-02 | Merck Patent Gmbh | Fusion proteins of interferon alpha muteins with improved properties |
WO2006127757A2 (en) * | 2005-05-26 | 2006-11-30 | Schering Corporation | Interferon-igg fusion |
WO2008140477A2 (en) * | 2006-11-02 | 2008-11-20 | Capon Daniel J | Hybrid immunoglobulins with moving parts |
-
2010
- 2010-11-29 WO PCT/IB2010/055474 patent/WO2011064758A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999058572A1 (en) * | 1998-05-08 | 1999-11-18 | Cambridge University Technical Services Limited | Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis |
WO2000069913A1 (en) * | 1999-05-19 | 2000-11-23 | Lexigen Pharmaceuticals Corp. | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
WO2002072605A2 (en) * | 2001-03-07 | 2002-09-19 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2004074486A2 (en) * | 2003-02-18 | 2004-09-02 | Merck Patent Gmbh | Fusion proteins of interferon alpha muteins with improved properties |
WO2006127757A2 (en) * | 2005-05-26 | 2006-11-30 | Schering Corporation | Interferon-igg fusion |
WO2008140477A2 (en) * | 2006-11-02 | 2008-11-20 | Capon Daniel J | Hybrid immunoglobulins with moving parts |
Non-Patent Citations (5)
Title |
---|
ARAI R ET AL: "Design of the linkers which effectively separate domains of a bifunctional fusion protein", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 8, 1 August 2001 (2001-08-01), pages 529 - 532, XP002334380, ISSN: 0269-2139, DOI: DOI:10.1093/PROTEIN/14.8.529 * |
JONES T D ET AL: "THE DEVELOPMENT OF A MODIFIED HUMAN IFN-ALPHA2B LINKED TO THE FC PORTION OF HUMAN IGG1 AS A NOVEL POTENTIAL THERAPEUTIC FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 24, no. 9, 1 September 2004 (2004-09-01), pages 560 - 572, XP009055485, ISSN: 1079-9907 * |
KOYAMA T ET AL: "Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication", HEPATOLOGY RESEARCH, AMSTERDAM, NL, vol. 34, no. 1, 1 January 2006 (2006-01-01), pages 41 - 49, XP025177312, ISSN: 1386-6346, [retrieved on 20060101], DOI: DOI:10.1016/J.HEPRES.2005.10.005 * |
LO K-M ET AL: "High level expression and secretion of Fc-X fusion proteins in mammalian cells", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 6, 1 June 1998 (1998-06-01), pages 495 - 500, XP002125745, ISSN: 0269-2139, DOI: DOI:10.1093/PROTEIN/11.6.495 * |
WANG L ET AL: "Enhanced circulation half-life for human IFNa2b and IgG Fc fusion protein", SHENG WU GONG CHENG XUE BAO = CHINESE JOURNAL OF BIOTECHNOLOGY, KEXUE CHUBANSHE, CN, vol. 24, no. 1, 25 January 2008 (2008-01-25), pages 53 - 62, XP008134213, ISSN: 1000-3061 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106456809A (en) * | 2013-12-03 | 2017-02-22 | 韦尔特生物分子医药有限责任公司 | Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof |
CN106456809B (en) * | 2013-12-03 | 2020-02-07 | 韦尔特生物分子医药有限责任公司 | Antibody targeting IgM bound to B cell receptor complex membrane and use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2011064758A2 (en) | 2011-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011064758A3 (en) | Fusion proteins of immunoglobulin fc and interferon- alpha | |
WO2013075066A3 (en) | Variant serum albumin with improved half -life and other properties | |
PH12016500081A1 (en) | Immunoglobulin variants and uses thereof | |
WO2014026054A3 (en) | CD20 scFv-ELPs METHODS AND THERAPEUTICS | |
WO2008143954A3 (en) | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto | |
WO2012064792A3 (en) | Protein complexes for antigen binding and methods of use | |
WO2013003641A3 (en) | Serpin fusion polypeptides and methods of use thereof | |
WO2011146891A3 (en) | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins | |
WO2014028777A3 (en) | Methods of treating a tauopathy | |
WO2012020006A3 (en) | Anti-fap antibodies and methods of use | |
WO2010120514A3 (en) | Antigen-binding proteins comprising recombinant protein scaffolds | |
WO2013184939A3 (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
WO2013152351A3 (en) | Fusion polypeptides and methods of use thereof | |
WO2010020766A3 (en) | Interleukin fusion polypeptides | |
NZ705370A (en) | Fcγriib-specific fc region variant | |
IL223989B (en) | Albumin binding polypeptide, fusion protein or conjugate comprising said polypeptide, polynucleotide encoding said albumin binding polypeptide and various aspects related thereto | |
WO2010106180A3 (en) | Optimized fc variants | |
WO2012142515A3 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
WO2010034032A3 (en) | Methods for preparing purified polypeptide compositions | |
WO2008157378A8 (en) | Rage fusion proteins | |
WO2012046061A3 (en) | Clostridium difficile antigens | |
WO2012139134A3 (en) | Methods of modulating oncogenic fusion proteins | |
WO2010082804A3 (en) | Method for producing physiologically active protein or peptide using immunoglobulin fragment | |
WO2012017324A3 (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
WO2013003649A3 (en) | Wap domain fusion polypeptides and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10805639 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10805639 Country of ref document: EP Kind code of ref document: A2 |